F-Tab

Quick links to important sections

F-Tab

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of F-Tab

What is F-Tab? A Quick Overview

Property Description
Active Ingredient (INN) Fluoxetine
Form Oral, Film-Coated Tablet
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Therapeutic Use Management of chronic mood and anxiety disorders
Origin Synthetic Compound

F-Tab is the commercial designation for a medication provided as an oral, film-coated tablet, with Fluoxetine as its active ingredient. This medication is clinically recognized as belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class. As a differentiating factor, F-Tab is often formulated for once-daily dosing, a feature valued for improved patient adherence.


What is F-Tab Made Of and Where Does It Come From?

The core substance of F-Tab is Fluoxetine, a synthetic compound manufactured entirely through controlled chemical processes. While many SSRIs share this synthetic origin, Fluoxetine is distinct for having a particularly long half-life, meaning it remains active in the body for an extended period, which contributes to its profile for managing chronic conditions. The chemical identity and quality standards of Fluoxetine are established through standard chemical identification.


What Is F-Tab Used For (General Therapeutic Purpose)?

The general therapeutic purpose of F-Tab is to provide sustained management for individuals diagnosed with specific long-term psychiatric conditions, such as major depressive disorder and obsessive-compulsive disorder. Its efficacy in treating these mood and affective disorders is recognized in clinical applications. This medication is intended for consistent, long-term use, focusing on establishing a neurochemical balance to help patients maintain a stable emotional state over many months of treatment, not for immediate or acute relief.

Regulatory References

  1. National Institute of Mental Health (NIH)
  2. National Institutes of Health

What side effects are possible with F-Tab?

Possible Side Effects and Safety Information: F-Tab

The safety profile of F-Tab is formally outlined in regulatory documents, classifying possible adverse reactions by frequency and the body system affected. These classifications structure the official understanding of the medicine’s risks.


Frequency-Classified Adverse Reactions

The incidence of documented adverse reactions is officially grouped into defined frequency tiers:

  • Very Common (Affecting ge 1 in 10 users): Insomnia, Headache, Diarrhea, Nausea, and Fatigue.
  • Common (Affecting ge 1 in 100 to < 1 in 10 users): Decreased appetite (anorexia), Anxiety, Nervousness, Decreased libido, Dizziness, Somnolence, Tremor, Dry mouth, and Rash.

Reactions are cataloged across System-Organ-Classes (SOC) including Psychiatric disorders, Nervous system disorders, Gastrointestinal disorders, and Skin and subcutaneous tissue disorders.


Serious Adverse Reactions and Safety Constraints

The regulatory safety profile mandates warnings for clinically significant adverse reactions, even if rare. These include Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like events, and an increased risk of Suicidal thoughts and behavior, particularly in pediatric and young adult patients. Severe cutaneous adverse reactions and significant Abnormal Bleeding events are also documented.

Population-Specific Notes: Safety considerations are specifically addressed for patients with severe hepatic impairment due to the risk of drug accumulation and for older adults regarding the potential for Hyponatraemia (low blood sodium).

Time-Related Patterns: Official labeling indicates that symptoms such as anxiety and nervousness may be more prominent during treatment initiation or dose adjustments.

Restrictions: A high-level safety constraint is the absolute contraindication against concurrent use with Monoamine Oxidase Inhibitors (MAOIs).

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Presentations

Overdose of F-Tab, which contains semaglutide, has been associated with an exaggeration of common gastrointestinal adverse effects. Symptoms can include severe nausea, severe vomiting, and severe abdominal pain. Due to the mechanism of action, overdose may also lead to severe hypoglycemia (low blood sugar), which can present as dizziness, confusion, sweating, or shakiness.

Required Emergency Actions

If an overdose is suspected, immediate medical attention is required. The long half-life of the active substance (approximately one week) necessitates that a prolonged period of observation and supportive treatment may be necessary to manage symptoms over an extended time.

If you believe you have taken too much F-Tab:

  • Seek emergency medical services by calling 911 (or local emergency number) immediately.
  • Initiate appropriate supportive treatment for symptoms, such as addressing low blood sugar.
  • You may also contact the Poison Help Line at 1-800-222-1222 or a medical toxicologist for additional management recommendations.

Overdose cases should be treated based on the specific clinical signs and symptoms a person is experiencing.

Therapeutic Uses of F-Tab

What F-Tab Treats: Main Uses and Benefits

F-Tab is a medication commonly used to help manage symptoms across therapeutic areas involving certain distressing symptoms. Its therapeutic applications are generally applied across domains where additional symptomatic support is needed. This includes use for conditions where symptoms may intensify temporarily or create noticeable functional strain.

The medication is relevant for easing symptoms in conditions such as Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Bulimia Nervosa, and Panic Disorder, as well as addressing Premenstrual Dysphoric Disorder (PMDD) and specific forms of treatment-resistant depression. Its use supports the maintenance of functional stability and may help patients cope more steadily with symptom fluctuations, particularly in chronic conditions.

“This medication is applied in clinical settings that involve acute or unstable symptom patterns, supporting the patient during difficult episodes when symptoms become more noticeable.”

Therapeutic Domains

F-Tab plays a role in managing conditions characterized by periods of heightened symptoms, where it is used for addressing symptom clusters related to persistent low mood, unwanted intrusive thoughts, and anxiety-driven behaviors. When symptoms create noticeable functional strain, supportive relief is provided, which may assist with maintaining functional stability and contributes to improved day-to-day comfort.

Quick Fact: Relief for Key Symptom Domains
Symptom Focus: Persistent low mood and recurrent intrusive thoughts.
Primary Benefit: Contributes to maintaining a sense of stability when symptoms are more noticeable.
Context: Commonly used for conditions requiring long-term symptomatic support.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use F-Tab?

F-Tab (Fluoxetine) eligibility is strictly defined by government regulatory documents based on contraindications, age limits, and pre-existing conditions.

Category Official Regulatory Classification
Allowed Use Established for adults across all indications. Approved for adolescents and children 8 years old for Major Depressive Disorder and 7 years old for Obsessive-Compulsive Disorder.
Contraindicated Use Prohibited for patients with known hypersensitivity or who are concurrently being treated with a Monoamine Oxidase Inhibitor (MAOI), pimozide, or thioridazine. Mandatory washout periods apply when transitioning from an MAOI.
Restricted Use A lower or less frequent dosage should be used for the elderly and for patients with hepatic impairment (e.g., cirrhosis). Use requires caution in patients with a history of seizures or risk factors for QT prolongation.
Age Limitations Safety and effectiveness are not established in pediatric patients below the minimum approved ages.
Reproductive Status Use during pregnancy is allowed only if the potential benefit justifies the potential risks. Breastfeeding is not recommended.

The official eligibility profile is structured by absolute contraindications, age-based limitations, and conditional use requirements for specific populations. Regulatory documents ensure that only defined patient groups are permitted to use the medicine under specific, official constraints.

What should I know about interactions with other medicines?

F-Tab Interactions with Other Medicines and Products

F-Tab's interaction profile is shaped by its high potency as an inhibitor of the CYP2D6 enzyme and its serotonergic activity, which is detailed in official regulatory documentation.

Contraindicated Combinations

The most restrictive classification is applied to certain combinations that are prohibited due to the high risk of severe reactions. These include all Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders, as well as Pimozide and Thioridazine. The latter two are contraindicated due to the documented risk of QT interval prolongation and elevated drug plasma levels. Linezolid and Intravenous Methylene Blue are also prohibited as they possess MAO-A inhibitory activity.

Pharmacokinetic and Pharmacodynamic Interactions

F-Tab is a potent inhibitor of the CYP2D6 isoenzyme, a major pharmacokinetic interaction that can cause a significant elevation of plasma concentrations for co-administered medicines metabolized by this pathway, such as certain Antipsychotics and Antiarrhythmics. Furthermore, co-administration with other serotonergic agents (e.g., Triptans, Tramadol, Lithium) is formally noted to increase the potential for Serotonin Syndrome due to additive pharmacodynamic effects.

Timing and Specific Constraints

Due to the long half-life of F-Tab and its active metabolite, a mandatory washout period of at least five weeks must elapse after discontinuation before beginning an MAOI. Conversely, F-Tab must not be started within 14 days of stopping an MAOI. Regulatory labeling also advises against co-administration with alcohol or substances that interfere with hemostasis, such as NSAIDs and Warfarin, due to an officially noted increased potential for bleeding. In the case of hepatic impairment, conditions that increase Fluoxetine exposure are noted as increasing the risk of cardiac events.

Mechanism of Action

Selective Serotonin Reuptake Inhibition

The initial mechanism of F-Tab is the selective and high-affinity inhibition of the Serotonin Transporter ( SERT), a protein on the presynaptic nerve membrane. By blocking SERT, the drug prevents the reuptake of the neurotransmitter serotonin ( 5-HT) from the synaptic cleft, resulting in an immediate and sustained elevation of 5-HT concentration available to stimulate postsynaptic receptors. This molecular action initiates the downstream physiological cascade.

Time-Dependent Neuroplasticity and Circuit Remodeling

The chronic presence of elevated 5-HT triggers adaptive changes in central neural circuits. Over a period of several weeks, this sustained modulation promotes neuroplasticity, influences the expression of Brain-Derived Neurotrophic Factor ( BDNF), and leads to the downregulation of certain postsynaptic 5-HT receptors. This complex, delayed remodeling process culminates in the long-term extbfreadjustment of neurochemical signaling within pathways associated with affective response.

Dosage and Administration Information

How F-Tab is Used: Official Administration Guidelines

F-Tab (Fluoxetine) is strictly intended for oral administration in the form of a tablet or capsule. The proper use of this medicine is defined by specific dosing schedules, administration timing, and population-specific considerations established in standard clinical protocols.


Official Dosing and Frequency

Administration is generally once daily (often recommended in the morning) and may be taken with or without food, as the drug's absorption is not significantly affected by meals.

Indication Starting Adult Dose (Daily) Maximum Recommended Dose (Daily)
Major Depressive Disorder (MDD) 20 mg 80 mg
Obsessive-Compulsive Disorder (OCD) 20 mg 80 mg
Bulimia Nervosa 60 mg (Target Dose) 60 mg

For higher doses (above 20 mg per day for MDD or OCD), the total daily dose may be administered as a divided dose (e.g., morning and noon).


Administration Procedure and Adjustments

Procedural Constraints

  • Titration Time: Dose increases should only be considered after several weeks of therapy (e.g., 4 to 5 weeks) to allow the medicine to reach stable levels in the body, reflecting its long half-life.
  • Dose Division: Some higher-strength tablets are functionally scored to permit precise division into smaller doses if necessary for titration.

Population-Specific Instructions

  • Hepatic Impairment: Patients with reduced liver function should be considered for a lower or less frequent dosage (e.g., alternate-day dosing) due to decreased clearance.
  • Older Adults: While maximum doses vary by region, caution is advised, and the total daily dose may be restricted to 40 mg to 60 mg per day.

Recent Clinical Evidence

Recent Clinical Evidence Summary

F-Tab is a first-in-class, non-opioid agent that has been investigated as a treatment for moderate to severe acute pain in adults. Its clinical development focused on its potential utility as an alternative to existing analgesics.

Key Clinical Trial Findings

Clinical data supporting the use of F-Tab was derived from two randomized, double-blind, placebo- and active-controlled studies. These trials primarily evaluated its effects on acute pain following surgical procedures, specifically abdominoplasty and bunionectomy.

  • Efficacy: Both trials examined the agent's impact on pain reduction following surgery. Studies reported a statistically significant reduction in pain scores for F-Tab compared to the placebo group. Participants in the trials were also permitted to use a common non-opioid analgesic as needed for rescue pain medication.

  • Safety Profile: The overall safety data was pooled from these and supportive studies involving over 800 participants. The most frequently reported adverse reactions across the trials included itching, muscle spasms, rash, and an increase in the blood level of creatine phosphokinase.

Ongoing and Future Research

Researchers are continuing to evaluate F-Tab's potential role in pain management beyond acute, short-term use. Investigative studies are currently exploring the agent’s effects on longer-term pain conditions, such as diabetic nerve pain and lumbosacral radiculopathy (sciatica), to understand its duration of action and effectiveness in chronic settings.

Frequently Asked Questions (FAQ)

Common questions about F-Tab (FAQ)

Q: How long does it usually take for F-Tab to start working?

Clinical studies supporting the drug's efficacy are typically evaluated over a period of several weeks of consistent use. This prolonged time is necessary for the medicine to reach stable levels in the body and for the required therapeutic changes to develop gradually.


Q: What should I expect in the first few days of using F-Tab?

Official safety documents indicate that some effects, such as anxiety and nervousness, may be more noticeable when first starting treatment or when the dosage is changed. These are documented possibilities during the initial adjustment period.


Q: Can F-Tab cause problems with sleeping?

Official documents list both insomnia (difficulty sleeping) as a very common reaction, and somnolence (drowsiness or feeling sleepy) as a common reaction. Changes to sleep patterns, such as difficulty sleeping or drowsiness, are noted among the documented adverse reactions.


Q: Can F-Tab be used at the same time as cold and flu medicine?

Certain common cold and flu medicines contain ingredients, such as serotonergic agents or non-steroidal anti-inflammatory drugs (NSAIDs), which are noted in labeling to potentially increase the risk of adverse reactions or bleeding when combined with F-Tab. Official documents note these potential overlaps in the interaction profile.


Q: Does F-Tab have a 'food interaction' warning?

The official administration instructions state that the medicine can be taken either with or without food. This is because meals do not significantly affect how the medicine is absorbed into the body.


Q: Are there different strengths or doses available for F-Tab?

The official product description details that F-Tab is manufactured in several different strengths and forms, including various tablet and capsule options. This range allows for use across different regulatory guidelines.


Q: Is F-Tab available as a generic medicine?

The active ingredient in F-Tab is Fluoxetine, which is widely available from multiple manufacturers as a generic option. F-Tab is the brand name designation for this specific medicine.


Q: Does F-Tab need to be refrigerated or stored in a special way?

Official regulatory documents define the storage conditions for F-Tab, which include keeping it at a controlled room temperature and protecting it from light and moisture. The labeling explicitly states that the product must not be frozen.


Q: Can F-Tab affect blood sugar levels?

Official safety documents have reported both decreases (hypoglycemia) and increases (hyperglycemia) in blood sugar levels as possible adverse reactions reported over time, under Metabolism and Nutrition Disorders.


Q: Does F-Tab affect hormone levels?

The medicine has been reported to have effects on hormone regulation. Documented adverse reactions include decreased libido and, rarely, the syndrome of inappropriate antidiuretic hormone secretion (SIADH), which reflects an effect on fluid-regulating hormones.


Q: What should I do if I miss a tablet of F-Tab?

The official prescribing information provides specific, non-personalized guidance on managing a missed dose. These instructions are intended to support adherence to the documented administration schedule.


Q: Does F-Tab cause weight gain or loss?

Weight changes are documented possibilities. Official documents list decreased appetite (anorexia) as a common adverse reaction, and both weight loss and, less frequently, weight gain have been observed in clinical trials.


Q: Is F-Tab a type of antibiotic?

No, F-Tab is classified as a Selective Serotonin Reuptake Inhibitor (SSRI). It is a medication used to manage chronic mood and anxiety disorders and is not a member of the antibiotic drug class.


Q: Does F-Tab work immediately after taking it?

Although the medicine begins blocking the serotonin transporter shortly after administration, the long-lasting nature of the drug and the time needed for the brain to adapt mean that the therapeutic effects are delayed. Clinical response is evaluated over several weeks.


Q: What happens if I stop using F-Tab suddenly?

Official regulatory documents define a specific procedure for discontinuing the dose, which includes a gradual reduction rather than abrupt cessation. This measure is intended to help avoid the potential development of discontinuation symptoms.


Q: How does F-Tab interact with alcohol?

Official regulatory labeling explicitly notes that the use of alcohol should be avoided while taking F-Tab. This caution is noted because the combination may increase the risk of adverse reactions.


Q: What is the tablet shape or color of F-Tab?

The physical description of the tablet, including its color, shape, and identifying imprints, is detailed in the official product information provided by the manufacturer. This information is intended to help users confirm the medication's identity.


Q: What is the purpose of the inactive ingredients in the F-Tab pill?

Inactive ingredients, also known as excipients, are listed in regulatory documents. These components are necessary to give the tablet its structure, stability, and physical properties, which supports the drug's shelf life and consistency.


Q: Is F-Tab addictive?

Based on clinical experience, official prescribing information suggests that F-Tab is not typically associated with drug-seeking behavior and dependence. It is not classified as a controlled substance.


Q: What is the clearance or duration of F-Tab in the body?

The drug has a long elimination half-life. This means the active medicine and its primary active metabolite remain in the body for an extended period, which contributes to its profile for chronic management.


Q: Can taking F-Tab make certain medical tests inaccurate?

The medicine may affect the results of certain laboratory tests, such as those monitoring sodium levels (hyponatraemia) and specific enzyme levels (creatine phosphokinase), which are noted in safety reports.


Q: Is F-Tab known to cause problems with kidney function?

While the drug is primarily processed by the liver, official documents caution about the risk of hyponatraemia (low sodium levels), which can be a concern for patients with pre-existing kidney conditions.


Q: Are there specific food types to avoid while using F-Tab?

Prescribing information does not list restrictions for specific food types to avoid. The primary cautionary guidance related to consumption is the advice against the use of alcohol.


Q: How is F-Tab different from placebo in research studies?

Clinical trials reported that F-Tab demonstrated a statistically significant reduction in pain scores in the treatment group compared to the group given a placebo, indicating a measurable difference in outcome.


Q: Is F-Tab safe to use before driving or operating machinery?

Official safety information includes warnings that the medicine may impair certain skills, such as judgment, thinking, or motor skills. This is due to potential central nervous system side effects like dizziness or somnolence.

How should F-Tab be stored and disposed of?

Official Storage and Disposal Instructions

F-Tab must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from light and kept away from excessive heat and moisture; the labeling explicitly states to not freeze the tablets.

To maintain stability, keep F-Tab in its original container and ensure the container is tightly closed when not in use. As a mandatory child-safety measure, all medication must be kept out of the sight and reach of children.

For disposal of unused or expired F-Tab, government guidelines recommend the use of a medicine take-back program. If a program is unavailable, the product should be removed from its container, mixed with an unappealing substance (like used coffee grounds or dirt), sealed in a bag, and then placed in the household trash. The regulatory instructions prohibit flushing F-Tab down a toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of F-Tab found in:

A-Z Index: